Zimmer Biomet has completed the acquisition of Monogram Technologies, an artificial intelligence (AI)-driven, next-gen orthopedic robotics company.

The company said Monogram’s surgeon-guided semi- and fully autonomous technologies will add new and differentiated capabilities to its broad suite of customer-centric tech solutions. Monogram’s CT-based, semi-autonomous, AI-navigated total knee arthroplasty (TKA) robotic tech earned U.S. Food and Drug Administration (FDA) 510(k) clearance in March 2025 and is anticipated for rollout with Zimmer Biomet implants by early 2027.

Monogram also began a clinical study in July for the fully autonomous version of the technology.

The deal bolsters Zimmer Biomet’s suite of orthopedic robotics, enabling solutions, and analytics to address surgeons’ needs before, during, and after surgery. The company’s portfolio includes imageless robotics through its ROSA robotics platform, a licensed CT-based handheld robot, mixed reality and AI-based navigation, and now Monogram’s robotics capabilities.

ROSA is quickly reaching 2,000 installations worldwide. The company is investing in an R&D pipeline featuring several new products and software applications expected between now and 2027. This includes ROSA Knee with OptimiZe, which was submitted for FDA 510(k) clearance that’s anticipated later this year, and other applications.

“By bringing Monogram into the Zimmer Biomet innovation ecosystem, we have set a bold course to become the first orthopedic company to offer a fully autonomous robotic solution complementing our current robotic and navigation offerings,” said Ivan Tornos, chairman, president and CEO of Zimmer Biomet. “We aim to provide surgeons the broadest choice in robotics and navigation across a wide range of procedures and care settings. I want to personally welcome the Monogram team to Zimmer Biomet, as their talent and technology will accelerate our innovation pipeline, deepen our value to surgeons and strengthen our long-term growth strategy.”

The company began the deal for Monogram in July. The deal had an equity value of about $177 million and an enterprise value of about $168 million.